Preliminary Program
Session times on those days will not be finalized until the overall program schedule is completed.
Program Tracks (Please click each Track for detailed program information) |
Track 2: Breakthroughs in Cancer Prognostics and Diagnostics |
Opening Ceremony and Keynote Forum
|
Time: 09:00-11:25, May 15, 2019 (Wednesday) |
|
| 09:00-09:15 | Opening Ceremony |
|
Moderator |
Dr. Luzhe Sun, Professor & Associate Director, University of Texas Health Science Center at San Antonio, USA |
|
09:15-09:20 |
Moderator's Introduction |
|
09:20-09:45 |
Title: Inhibition of Ductal Carcinoma in situ to Invasive Breast Cancer |
|
09:45-10:10 |
Title: Endometriosis and Adenomyosis as Biologic Behavior Modulators of Gynecologic Malignancies |
|
10:10-10:35 |
Title: Pre-Clinical Investigation of NKTR-255, a Polymer-Conjugated Human IL-15 with a Potent NK Cell Dependent Anti-Tumor Efficacy |
|
10:35-11:00 |
Title: Clindamycin/Primaquine, at 30 Years, for Treating Pneumocystis Jirovecii Pneumonia |
|
11:00-11:25 |
Dr. Vladimir Lazar, Chief Scientific and Operating Officer, WIN Consortium, France |
BIT Group Global Ltd.
Japan-China Business Co., Ltd.
日中商務株式会社
Dr. Vladimir Lazar
Chief Scientific and Operating Officer
WIN Consortium, France
Dr. Ashok Srivastava
Chief Executive Officer & Chief Medical Officer, ClinFomatrix, Cure Pharmaceuticals, Inc, USA
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2008-2019 BIT Congress Inc.